| Name | Title | Contact Details |
|---|
Millcreek Behavioral Health is a residential treatment center in Arkansas for children and adolescents struggling with depression, addiction, bipolar, aggression, and sexual reactive behaviors.
Cummins Behavioral Health Systems is a Avon, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Gentiva Health Services (NASDAQ: GTIV), formerly based in Melville, Long Island, New York and now in Atlanta, Georgia, is the largest provider of home health care, hospice and related services in the United States. Gentiva is a Fortune 1000 company with $1.7 billion in annual revenue. Gentiva is also a member of the S&P 600 index, developed by Standard and Poor's, featuring small capitalization U.S.-based stocks. The company offers a range of services, including nursing, physical, occupational, and speech-language therapy, cardiac and pulmonary care, disease and pain management, and other health and medical services. Gentiva provides health services to over half a million patients annuallythrough over 380 U.S. locations in 39 states. According to Morningstar, "Gentiva is a gentle giant...the nation's largest home health care services firm." Gentiva companies include Donelson, Emerald Coast, Gilbert's, Healthfield Group, Heritage, Horizon, Hospice of Charleston, Lazarus House, Tar Heel, Total Care and Wiregrass."
Berks Community Health Center is a freestanding, non-profit Federally Qualified Health Center, providing patient-centered, affordable, high-quality primary health care.
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.